<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006233830
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIRA 25 mg TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMOTRIGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamira belongs to a group of medicines called <em>anti-epileptics</em>. It is used to treat two conditions - <strong>epilepsy </strong>and <strong>bipolar disorder</strong>.</p><p>&nbsp;</p><p><strong>Lamira treats epilepsy </strong>by blocking the signals in the brain that trigger epileptic seizures (fits).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; For adults and children aged 13 years and over, Lamira can be used on its own or with other medicines, to treat epilepsy. Lamira can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; For children aged between 2 and 12 years, Lamira can be used with other medicines, to treat those conditions. It can be used on its own to treat a type of epilepsy called typical absence seizures.</p><p>&nbsp;</p><p><strong>Lamira also treats bipolar disorder. </strong></p><p>People with bipolar disorder (sometimes called <em>manic depression</em>) have extreme mood swings, with periods of mania (excitement or euphoria) alternating with periods of depression (deep sadness or despair). For adults aged 18 years and over, Lamira can be used on its own or with other medicines, to prevent the periods of depression that occur in bipolar disorder. It is not yet known how Lamira works in the brain to have this effect.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lamira: </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic </strong>(<em>hypersensitive</em>) to lamotrigine or any of the other ingredients of this medicine (listed in Section 6).</p><p>&nbsp;</p><p>If this applies to you:</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>and don&rsquo;t take Lamira.</p><p>&nbsp;</p><p><strong>Take special care with Lamira</strong></p><p><strong>Talk to your doctor or pharmacist before taking Lamira: </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have any kidney problems </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have ever developed a rash </strong>after taking lamotrigine or other medicines for bipolar disorder or epilepsy</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have ever developed meningitis after taking lamotrigine</strong>(<em>read the description of these symptoms in Section 4 of this leaflet</em>: <em>Other side effects</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are already taking medicine that contains lamotrigine</strong>.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have a condition called Brugada syndrome. </strong>Brugada syndrome is a genetic disease that results in abnormal electrical activity within the heart. ECG abnormalities which may lead to arrhythmias (abnormal heart rhythm) can be triggered by lamotrigine.<strong> </strong></p><p>&nbsp;</p><p>If any of these applies to you:</p><p><strong>Tell your doctor</strong>, who may decide to lower the dose or that Lamira is not suitable for you.</p><p>&nbsp;</p><p><strong>Important information about potentially life-threatening reactions </strong></p><p>A small number of people taking Lamira get an allergic reaction or potentially life-threatening skin reaction, which may develop into more serious problems if they are not treated. You need to know the symptoms to look out for while you are taking Lamira.</p><p>&nbsp;</p><p><strong>Read the description of these symptoms in Section 4 of this leaflet </strong>under &lsquo;<em>potentially life-threatening reactions</em>: <em>get a doctor&rsquo;s help straight away</em>&rsquo;.</p><p>&nbsp;</p><p><strong>Thoughts of harming yourself or suicide </strong></p><p>Anti-epileptic medicines are used to treat several conditions, including epilepsy and bipolar disorder. People with bipolar disorder can sometimes have thoughts of harming themselves or committing suicide. If you have bipolar disorder, you may be more likely to think like this:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; when you first start treatment</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; if you have previously had thoughts about harming yourself or about suicide</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; if you are under 25 years old.</p><p>&nbsp;</p><p>If you have distressing thoughts or experiences, or if you notice that you feel worse or develop new symptoms while you&rsquo;re taking Lamira:</p><p>&nbsp;</p><p><strong>See a doctor as soon as possible or go to the nearest hospital for help. </strong></p><p>&nbsp;</p><p>A small number of people being treated with anti-epileptics such as Lamira have also had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p>&nbsp;</p><p><strong>If you&rsquo;re taking Lamira for epilepsy </strong></p><p>The seizures in some types of epilepsy may occasionally become worse or happen more often while you&rsquo;re taking Lamira. Some patients may experience severe seizures, which may cause serious health problems. If your seizures happen more often or if you experience a severe seizure while you&rsquo;re taking Lamira:</p><p><strong>See a doctor as soon as possible</strong>.</p><p>&nbsp;</p><p><strong>Lamira should not be given to people aged under 18 years to treat bipolar disorder</strong>. Medicines to treat depression and other mental health problems increase the risk of suicidal thoughts and behaviour in children and adolescents aged under 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Lamira</strong></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines </strong>including herbal medicines or other medicines bought without a prescription.</p><p>&nbsp;</p><p>Your doctor needs to know if you are taking other medicines to treat epilepsy or mental health problems. This is to make sure you take the correct dose of Lamira. These medicines include:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>oxcarbazepine, felbamate, gabapentin, levetiracetam, pregabalin, topiramate</strong>or <strong>zonisamide</strong>, used to treat <strong>epilepsy </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>lithium, olanzapine </strong>or <strong>aripiprazole</strong>used to treat <strong>mental health problems </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>bupropion, </strong>used to treat <strong>mental health problems </strong>or to <strong>stop smoking </strong></p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if you are taking any of these.</p><p>&nbsp;</p><p>Some medicines interact with Lamira or make it more likely that people will have side effects. These include:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>valproate</strong>, used to treat <strong>epilepsy </strong>and <strong>mental health problems </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine</strong>, used to treat <strong>epilepsy </strong>and <strong>mental health problems </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>phenytoin, primidone</strong>or <strong>phenobarbitone</strong>, used to treat <strong>epilepsy </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>risperidone</strong>, used to treat <strong>mental health problems </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong>, which is an <strong>antibiotic </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>Human Immunodeficiency Virus (HIV) infection </strong>(a combination of lopinavir and ritonavir or atazanavir and ritonavir)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>hormonal contraceptives</strong>, such as <strong>the Pill </strong>(<em>see below</em>).</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if you are taking any of these or if you start or stop taking any.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Hormonal contraceptives (such as the Pill) can affect the way Lamira works </strong></p><p>Your doctor may recommend that you use a particular type of hormonal contraceptive or another method of contraception, such as condoms, a cap or coil. If you are using a hormonal contraceptive like the Pill, your doctor may take samples of your blood to check the level of Lamira. If you are using a hormonal contraceptive or if you plan to start using one:</p><p><strong>Talk to your doctor, </strong>who will discuss suitable methods of contraception with you.</p><p>&nbsp;</p><p>Lamira can also affect the way hormonal contraceptives work, although it&rsquo;s unlikely to make them less effective. If you are using a hormonal contraceptive and you notice any changes in your menstrual pattern, such as breakthrough bleeding or spotting between periods:</p><p><strong>Tell your doctor</strong>. These may be signs that Lamira is affecting the way your contraceptive is working.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>There may be an increased risk of birth defects in babies whose mothers took Lamira during pregnancy. These defects include cleft lip or cleft palate. Your doctor may advise you to take extra <strong>folic acid </strong>if you&rsquo;re planning to become pregnant and while you&rsquo;re pregnant.</p><p>&nbsp;</p><p>Pregnancy may also alter the effectiveness of Lamira, so you may need blood tests and your dose of Lamira may be adjusted.</p><p><strong>If you are pregnant, think you may be pregnant or are planning to have a baby ask your doctor or pharmacist for advice before taking this medicine. You should not stop treatment without discussing this with your doctor. </strong>This is particularly important if you have epilepsy.</p><p>&nbsp;</p><p><strong>If you are breast-feeding or planning to breast-feed ask your doctor or pharmacist for advice before taking this medicine</strong>. The active ingredient of Lamira passes into breast milk and may affect your baby. Your doctor will discuss the risks and benefits of breast-feeding while you&rsquo;re taking Lamira and will check your baby from time to time if you decide to breast-feed.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Lamira can cause dizziness and double vision.</p><p><strong>Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected. </strong></p><p>&nbsp;</p><p><strong>If you have epilepsy, talk to your doctor about driving and using machines</strong>.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Lamira</strong></p><p>Lamira tablets contain small amounts of a sugar called lactose. If you have an intolerance to lactose or any other sugars:</p><p><strong>Tell your doctor </strong>and don&rsquo;t take Lamira.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you</strong>. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much Lamira to take &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>It may take a while to find the best dose of Lamira for you. The dose you take will depend on:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; your age</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; whether you are taking Lamira with other medicines</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; whether you have any kidney or liver problems.</p><p>&nbsp;</p><p>Your doctor will prescribe a low dose to start and gradually increase the dose over a few weeks until you reach a dose that works for you (called the <em>effective dose</em>). <strong>Never take more Lamira than your doctor tells you to</strong>.</p><p>&nbsp;</p><p>The usual effective dose of Lamira for adults and children aged 13 years or over is between 100 mg and 400 mg each day.</p><p>&nbsp;</p><p>For children aged 2 to 12 years, the effective dose depends on their body weight - usually, it&rsquo;s between 1 mg and 15 mg for each kilogram of the child&rsquo;s weight, up to a maximum maintenance dose of 200 mg daily.</p><p>&nbsp;</p><p>Lamira is not recommended for children aged under 2 years.</p><p>&nbsp;</p><p><strong>How to take your dose of Lamira</strong></p><p>Take your dose of Lamira once or twice a day, as your doctor advises. It can be taken with or without food.</p><p>&nbsp;</p><p>Your doctor may also advise you to start or stop taking other medicines, depending on what condition you&rsquo;re being treated for and the way you respond to treatment.</p><p>&nbsp;</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swallow your tablets whole</strong>. Don&rsquo;t break, chew or crush them.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>Always take the full dose </strong>that your doctor has prescribed. Never take only part of a tablet.</p><p>&nbsp;</p><p><strong>If you take more Lamira than you should </strong></p><p><strong>Contact a doctor or pharmacist immediately</strong>. If possible, show them the Lamira packet.</p><p>&nbsp;</p><p>Someone who has taken too much Lamira may have any of these symptoms:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; rapid, uncontrollable eye movements (<em>nystagmus</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; clumsiness and lack of co-ordination, affecting their balance (<em>ataxia</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; heart rhythm changes (detected usually on ECG)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness or coma.</p><p>&nbsp;</p><p><strong>If you forget to take Lamira</strong></p><p><strong>Don&rsquo;t take extra tablets to make up for a missed dose. Just take your next dose at the usual time. </strong></p><p><strong>Ask your doctor for advice on how to start taking it again</strong>. It&rsquo;s important that you do this.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop taking Lamira without advice </strong></p><p>Lamira must be taken for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to.</p><p>&nbsp;</p><p><strong>If you&rsquo;re taking Lamira for epilepsy </strong></p><p>To stop taking Lamira, <strong>it is important that the dose is reduced gradually</strong>, over about 2 weeks. If you suddenly stop taking Lamira, your epilepsy may come back or get worse.</p><p>&nbsp;</p><p><strong>If you&rsquo;re taking Lamira for bipolar disorder </strong></p><p>Lamira may take some time to work, so you are unlikely to feel better straight away. If you stop taking Lamira, your dose will not need to be reduced gradually but you should still talk to your doctor first, if you want to stop taking Lamira.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, but not everyone gets them.</p><p>&nbsp;</p><p><strong>Potentially life-threatening reactions: get a doctor&rsquo;s help straight away </strong></p><p>A small number of people taking Lamira get an allergic reaction or potentially life-threatening skin reaction, which may develop into more serious problems if they are not treated.</p><p>&nbsp;</p><p>These symptoms are more likely to happen during the first few months of treatment with Lamira, especially if the starting dose is too high or if the dose is increased too quickly or if Lamira is taken with another medicine called <em>valproate</em>. Some of the symptoms are more common in children, so parents should be especially careful to watch out for them.</p><p>&nbsp;</p><p>Symptoms of these reactions include:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>skin rashes or redness</strong>, which may develop into life-threatening skin reactions including widespread rash with blisters and peeling skin, particularly occurring around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>), extensive peeling of the skin (more than 30% of the body surface - <em>toxic epidermal necrolysis</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>ulcers in the mouth, throat, nose or genitals </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>a sore mouth or red or swollen eyes </strong>(<em>conjunctivitis</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>a high temperature </strong>(<em>fever</em>), flu-like symptoms or drowsiness</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>swelling around your face </strong>or <strong>swollen glands </strong>in your neck, armpit or groin</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>unexpected bleeding or bruising</strong>, or the fingers turning blue</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; <strong>a sore throat </strong>or more infections (such as colds) than usual.</p><p>In many cases, these symptoms will be signs of less serious side effects <strong>but you must be aware that they are potentially life-threatening and can develop into more serious problems, </strong>such as organ failure, if they are not treated. If you notice any of these symptoms:</p><p><strong>Contact a doctor immediately</strong>. Your doctor may decide to carry out tests on your liver, kidneys or blood and may tell you to stop taking Lamira. In case you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis your doctor will tell you that you must never use lamotrigine again.</p><p>&nbsp;</p><p><strong>Very common side effects </strong></p><p>These may affect <strong>more than 1 in 10 </strong>people:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; skin rash.</p><p>&nbsp;</p><p><strong>Common side effects </strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; aggression or irritability</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy or drowsy</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; shaking or tremors</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping (<em>insomnia</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>) or being sick (<em>vomiting</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; pain in your back or joints, or elsewhere.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; clumsiness and lack of co-ordination (<em>ataxia</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; double vision or blurred vision.</p><p>&nbsp;</p><p><strong>Rare side effects </strong></p><p>These may affect <strong>up to 1 in 1,000 </strong>people:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a life-threatening skin reaction (<em>Stevens-Johnson syndrome</em>): <em>see also the information at the beginning of Section 4 </em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a group of symptoms together including: fever, nausea, vomiting, headache, stiff neck and extreme sensitivity to bright light. This may be caused by an inflammation of the membranes that cover the brain and spinal cord (<em>meningitis</em>). These symptoms usually disappear once treatment is stopped however if the symptoms continue or get worse <strong>contact your doctor </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; rapid, uncontrollable eye movements (<em>nystagmus</em>)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; itchy eyes, with discharge and crusty eyelids (<em>conjunctivitis</em>).</p><p>&nbsp;</p><p><strong>Very rare side effects </strong></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a life-threatening skin reaction (<em>toxic epidermal necrolysis</em>): <em>see also the information at the beginning of Section 4 </em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a high temperature (<em>fever</em>): <em>see also the information at the beginning of Section 4 </em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; swelling around the face (<em>oedema</em>) or swollen glands in the neck, armpit or groin (<em>lymphadenopathy</em>): <em>see also the information at the beginning of Section 4 </em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; changes in liver function, which will show up in blood tests, or liver failure: <em>see also the information at the beginning of Section 4 </em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a serious disorder of blood clotting, which can cause unexpected bleeding or bruising (<em>disseminated intravascular coagulation</em>): <em>see also the information at the beginning of Section 4.</em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; changes which may show up in blood tests - including reduced numbers of red blood cells (<em>anaemia</em>), reduced numbers of white blood cells (<em>leucopenia, neutropenia, agranulocytosis</em>), reduced numbers of platelets (<em>thrombocytopenia</em>), reduced numbers of all these types of cell (<em>pancytopenia</em>) and a disorder of the bone marrow called <em>aplastic anaemia</em></p><p>●&nbsp;&nbsp;&nbsp;&nbsp; hallucinations (&lsquo;seeing&rsquo; or &lsquo;hearing&rsquo; things that aren&rsquo;t really there)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; feeling &lsquo;wobbly&rsquo; or unsteady when you move about</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable body movements (<em>tics</em>), uncontrollable muscle spasms affecting the eyes, head and torso (<em>choreoathetosis</em>) or other unusual body movements such as jerking, shaking or stiffness</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; in people who already have epilepsy, seizures happening more often</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; in people who already have Parkinson&rsquo;s disease, worsening of the symptoms.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; lupus-like reaction (symptoms may include: back or joint pain which sometimes may be accompanied by fever and/or general ill health).</p><p>&nbsp;</p><p><strong>Other side effects </strong></p><p>Other side effects have occurred in a small number of people but their exact frequency is unknown:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term anti-epileptic medication, have a history of osteoporosis or take steroids.</p><p>&nbsp;</p><p><strong>If you get side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date shown on the blisters or carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Lamira does not require any special storage conditions.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. This will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lamotrigine. Each tablet contains 25 mg lamotrigine.</p><p>&nbsp;</p><p>The other ingredients are: lactose BP 200, Avicel PH 101, povidone30, sodium starch glycolate , iron oxide yellow, purified water, Avicel PH 102, colloidal silicon dioxide and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamira 25 mg tablets are yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with “37” on one side and plain on the other side.

Each unit carton contains 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Spimaco</strong></p><p>&nbsp;</p><p>AlQassim pharmaceutical plant</p><p>&nbsp;</p><p>Saudi Pharmaceutical Industries &amp;</p><p>&nbsp;</p><p>Medical Appliance Corporation.</p><p>&nbsp;</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2019.  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي لاميرا الي مجموعة من الأدوية تسمي مضادات الصرع. والتي تستخدم في علاج نوعين من الحالات وهما الصرع والاضطراب ثنائي القطب.</p><p>&nbsp;</p><p><strong>يعالج لاميرا الصرع</strong> عن طريق منع الاشارات الدماغية التي تزيد من حدوث نوبات الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للبالغين والأطفال الذين تتراوح أعمارهم بين 13 سنة وما يزيد، يمكنهم استخدام لاميرا بمفردها أو مع غيرها من الأدوية لعلاج حالات الصرع. ويمكن ايضا استخدام لاميرا مع غيرها من الأدوية لعلاج النوبات التي تحدث مع حالة تسمي متلازمة لينوكس جاستو.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للأطفال الذين تتراوح اعمارهم بين 2 و 12 سنة، يمكنهم استخدام لاميرا مع غيرها من الأدوية لعلاج هذه الحالات. ويمكن استخدامه بمفرده لعلاج نوع من الصرع يسمي غياب التشنجات النموذجية.</p><p><strong>&nbsp;يمكن أيضا استخدام لاميرا في علاج اضطراب ثنائي القطب.</strong></p><p>&nbsp;الأشخاص الذين يعانون من الأضطراب ثنائي القطب (والتي تسمي احيانا الإكتئاب الهوسي) لديهم تقلبات مزاجية ، مع فترات من الهوس (الإثارة أو النشوة) بالتناوب مع فترات من الإكتئاب (الحزن العميق أو اليأس).</p><p>للبالغين الذين تتراوح أعمارهم بين 18 سنة وما يزيد، يمكنهم استخدام لاميرا بمفردها أو مع غيرها من الأدوية، لمنع فترات الإكتئاب التي تحدث في الاضطراب ثنائي القطب. ولم يعرف حتي الأن كيفية عمل اللاميرا في المخ ليصبح لها هذا التأثير.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>امتنع عن تناول أقراص اللاميرا &nbsp;واخبر طبيبك فى الحالات الآتية:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية من مادة اللاموتريجين أو أي من مكونات هذ الدواء (المذكورة في الفقرة 6).</p><p>إذا انطبق عليك هذا:</p><p>&nbsp; عليك التواصل مع طبيبك والتوقف عن تناول اللاميرا.</p><p><strong>ينبغى توخى الحذر عند تناول أقراص اللاميرا فى الحالات الآتية:</strong></p><p>ينبغى اخبار طبيبك او الصيدلي إذا كنت تعانى أو عانيت من أى من الحالات التالية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في الكلي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا اصبت من قبل بطفح جلدي بعد تناولك اللاموتريجين أو غيره من الأدوية التي تستخدم في علاج الاضطراب الثنائي القطب أو الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا اصبت من قبل بالتهاب السحايا بعد تناول اللاموتريجين (اقرأ وصف هذه الأعراض في الفقرة 4 من هذه النشرة : الأثار الجانبية الأخري).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بالفعل دواء يحتوي علي اللاموتريجين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حالة تسمى متلازمة بروجادا. متلازمة بروجادا هي مرض وراثي يؤدي إلى نشاط كهربائي غير طبيعي داخل القلب. اضطرابات تخطيط القلب التي قد تؤدي إلى عدم انتظام ضربات القلب (حدوث خلل فى إيقاع القلب) يمكن أن يكون سببها لاموتريجين.</p><p>إذا انطبقت عليك إحدي هذه الحالات:</p><p>ينبغي اخبار طبيبك في حالة إذا انطبق عليك احدي هذه الحالات ، لكي يقرر إذا كان سيقوم بتقليل جرعة الدواء الخاصة بك أو أن الدواء غير مناسب لك.</p><p><strong>معلومات هامة حول آثار جانبية قد تكون مهددة للحياة</strong></p><p>هناك عدد قليل من الأشخاص الذين يتناولون اللاميرا قد يصابون بتفاعل تحسسي أو أثار جانبية علي الجلد مهددة للحياة، والتي قد تتطور إلي مشاكل أكثر خطورة إذا لم تتم معالجتها. قد تحتاج إالي معرفة هذه الأعراض لترقبها أثناء تناول اللاميرا.</p><p>اقرأ وصف هذه الأعراض في الفقرة 4 من هذه النشرة تحت عنوان ( الأثار الجانبية المهددة للحياة : عليك الحصول علي مساعدة الطبيب علي الفور).</p><p><strong>الأفكار الخاصة بإيذاء النفس أو الإنتحار</strong></p><p>تستخدم الأدوية المضادة للإكتئاب في علاج حالات متعددة، بما في ذلك الصرع والاضطراب الثنائي القطب. قد يراود المرضي المصابين بالاضطراب ثنائي القطب أفكارا تدعوهم لإيذاء أنفسهم أو الإنتحار.</p><p>إذا كنت مصابا بالاضطراب ثنائي القطب، قد تكون أكثر عرضة للتفكير في الأتي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متي بدأت مرحلة العلاج.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك من قبل أفكارا حول إيذاء نفسك أو الانتحار.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك أقل من 25 سنة.</p><p>إذا كان لديك أفكار أو تجارب مؤلمة، أو إذا لاحظت أن حالتك تسوء أو في حالة ظهور أعراض جديدة أثناء تناولك اللاميرا:</p><p><strong>عليك مراجعة الطبيب في أقرب وقت ممكن أو الذهاب إلي أقرب مستشفي للحصول علي المساعدة.</strong></p><p>هنالك عدد قليل ممن يعالجون باستخدام مضادات الصرع مثل اللاميرا قد يكون لديهم بعض الأفكار التي تتعلق بإيذاء أو قتل النفس، إذا راودتك أي من هذه الأفكار في أي وقت فعليك الاتصال بطبيبك فورا.</p><p><strong>إذا كنت ممن يتناولون اللاميرا في حالات الصرع</strong></p><p>قد تصبح النوبات في بعض أنواع الصرع أحيانا أكثر سوءا أو تكرارا عند استخدامك للاميرا. بعض المرضي قد يصابون بنوبات شديدة، والتي قد تتسبب في مشاكل صحية خطيرة. إذا أصبحت النوبات تتكرر بشكل أكبر أو أشد خطورة أثناء تناولك للاميرا :</p><p><strong>فعليك مراجعة طبيبك في أقرب وقت ممكن.</strong></p><p><strong>لا يجب استخدام اللاميرا لمن تقل أعمارهم عن 18 سنة في علاج الاضطراب ثنائي القطب. </strong>الأدوية المستخدمة في علاج الإكتئاب وغيرها من مشاكل الصحة العقلية تزيد من خطر السلوك والأفكار الانتحارية لدي الأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</p><p><strong>تناول اللاميرا مع أدوية أخري:</strong></p><p>عليك اخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت قريبا أو من الممكن أن تتناول أي دواء أخر بما في ذلك الأدوية العشبية أو أي من الأدوية الأخري اللاوصفية.</p><p>يحتاج طبيبك إلي معرفة إذا كنت تتناول أي ادوية أخري لعلاج الصرع أو أي مشاكل تخص الصحة العقلية.</p><p>ويكون هذا للتأكد من تناولك الجرعة الصحيحة من اللاميرا، وتتضمن هذه الأدوية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسكاربازيبين، فيلبامات، جابابنتين، ليفيتيراسيتام، بريجابالين، توبيرامات أو زونيسامايد، والتي تستخدم في علاج الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم، اولانزابين، اريبيبرازول والتي تستخدم في علاج مشاكل الصحة النفسية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيوبروبيون، والتي تستخدم في علاج مشاكل الصحة النفسية أو لإيقاف التدخين.</p><p><strong>عليك اخبار طبيبك </strong>في حالة تناولك أي من هذه الأدوية.</p><p>هناك بعض الأدوية التي تتفاعل مع اللاميرا أو تتسبب للمرضي في ظهور الأثار الجانبية ، وتتضمن:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فالبروات، والذي يستخدم في علاج الصرع ومشاكل الصحة النفسية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، والذي يستخدم في علاج الصرع ومشاكل الصحة النفسية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، بريميدون أو فينوباربيتون، والتي تستخدم في علاج الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريسبيريدون، والذي يستخدم في علاج مشاكل الصحة النفسية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رفامبيسين (مضاد حيوي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج عدوي نقص المناعة الفيروسي (الإيدز) ( محموعة من اللوبينافير و الريتونافير أو الأتازانافير و الريتنوفير ).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل، مثل الأقراص (تابع في الأسفل).</p><p><strong>عليك اخبار طبيبك</strong> إذا كنت تتناول أيا من هذه الأدوية أو بدأت في تناولها أو توقفت عن تناول أي منها.</p><p><strong>موانع الحمل (مثل الأقراص) قد تؤثر علي فاعلية أداء اللاميرا</strong></p><p>قد ينصح طبيبك باستخدام نوع معين من موانع الحمل أو أي طريقة أخري من موانع الحمل، مثل استخدام الأوقية الذكرية، القبعة أو اللفائف. في حالة استخدامك لوسيلة منع ححمل مثل الأقراص، يقوم الطبيب بأخذ عينات للتأكد من معدل اللاميرا في الدم. في حالة استخدامك وسيلة لمنع الحمل أو إذا كنتي تخططين لاستخدام أي منها<strong>:</strong></p><p><strong>عليك اخبار طبيبك</strong>، والذي بإمكانه مناقشة وسائل منع الحمل المناسبة لك.</p><p>قد تؤثر اللاميرا أيضا علي أداء وسيلة منع الحمل، بالرغم من انه من غير المرجح أن تجعلها أقل فعالية. في حالة استخدامك وسيلة منع حمل ولاحظتي أي تغير في نمط الطمث، مثل أي اجتياح للنزيف أو اي علامة بين الدورات:</p><p><strong>عليك اخبار طبيبك</strong>، لأنها من الممكن أن تكون علامات علي أن اللاميرا يؤثر علي فعالية أداء وسيلة منع الحمل.</p><p><strong>الحمل والرضاعة</strong></p><p>قد يكون هناك خطر متزايد من العيوب الخلقية لدي الأطفال في حالة تناول أمهاتهم اللاميرا أثناء الحمل، وتشمل هذه العيوب الشفة المشقوقة أو الحنك المشقوق. قد ينصح طبيبك بأن تستخدمي مزيد من حمض الفوليك إذا كنتي تخططين أن تكوني حاملا وأثناء الحمل.</p><p>قد يؤثر الحمل علي فعالية اللاميرا، لذا يتوجب عمل تحاليل دم مع تعديل جرعة اللاميرا.</p><p><strong>إذا كنتي حاملا، أو تعتقدين بأنك حاملا، أو تخططين لإنجاب طفل فعليك أن تسألي طبيبك أو الصيدلي المشورة قبل تناول هذا الدواء. ويتوجب عليكي عدم التوقف عن العلاج دون مشاورة طبيبك</strong>. وهذا مهم بشكل خاص إذا كنتي مصابة بالصرع.</p><p><strong>إذا كنتي تقومين بالرضاعة الطبيعية أو تخططين لذلك فعليكي أن تسألي الطبيب أو الصيدلي المشورة قبل تناول هذا الدواء.</strong> المادة الفعالة في اللاميرا تستطيع العبور الي لبن الثدي وبالتالي التأثير علي الطفل. سوف يقوم طبيبك بمشاورة المخاطر والمنافع من الرضاعة الطبيعية أثناء تناولك اللاميرا وسوف يقوم بفحص الطفل من حين لأخر إذا أخذتي قرار أن تقومين بالرضاعة الطبيعية.</p><p><strong>القيادةواستعمال الآلات</strong></p><p>قد يتسبب اللاميرا في الدوخة وضع الرؤية.</p><p>لا تقوم بالقيادة أو استخدام الآلات إذا لم تكن متأكدا من أنك لن تتأثر.</p><p>إذا كنت مصابا بالصرع، تحدث الي طبيبك عن القيادة واستخدام الآلات.</p><p><strong>معلومات هامة عن بعض العناصر المكونة لللاميرا&nbsp; </strong></p><p>يحتوي اللاميرا علي كميات صغيرة من سكر اللاكتوز. إذا كنت مصابا بالحساسية المفرطة من اللاكتوز أو أي من السكريات الأخري:</p><p><strong>عليك أن تخبر طبيبك</strong> ولا تتناول اللاميرا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. إذا كنت غير واثق يجب عليك التحقق من خلال الطبيبأو الصيدلى.</p><p><strong>جرعة اللاميرا</strong></p><p>تحديد الجرعة المناسبة لك من اللاميرا قد يستغرق بعض الوقت. وتعتمد الجرعة التي تتناولها علي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمرك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول اللاميرا مع أدوية أخري.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمشاكل في الكلي أو الكبد.</p><p>&nbsp;</p><p>سوف يقوم طبيبك بوصف جرعة قليلة في البداية ثم يقوم بزيادتها تدريجيا علي مدار عدة أسابيع حتي يصل إلي الجرعة المناسبة لك (تسمي الجرعة الفعالة). لا تتناول مطلقا أي جرعة اضافية من اللاميرا تزيد عن الجرعة التي وصفها طبيبك.</p><p>&nbsp;</p><p>الجرعة الفعالة المعتادة من اللاميرا للبالغين والأطفال الذين تتراوح أعمارهم بين 13 سنة فما فوق هي تتراوح بين 100 ملجم و 400 ملجم يوميا.</p><p>&nbsp;</p><p>أما بالنسبة للأطفال الذين تتراوح أعمارهم بين 2 الي 12 سنة، الجرعة الفعالة تعتمد علي وزن الجسم، عادة تكون بين 1 ملجم الي 15 ملجم لكل كيلوجرام من وزن الطفل، علي أن تكون الجرعة القصوي للحماية هي 200 ملجم يوميا.</p><p>&nbsp;</p><p>لا ينصح باستخدام لاميرا للأطفال الذين تقل أعمارهم عن سنتين.</p><p>&nbsp;</p><p><strong>كيف تتناول جرعة اللاميرا</strong></p><p>قم بتناول جرعتك من اللاميرا مرة أو مرتين في اليوم، تبعا لمشورة الطبيب. من الممكن تناول الجرعة سواء مع الأكل أو بدونه.</p><p>&nbsp;</p><p>قد يقوم طبيبك بالمشورة لكي تبدأ أو تتوقف عن استخدام أدوية أخري، تبعا لحالتك المرضية وطريقة استجابتك للعلاج.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم ببلع القرص بأكمله. لا تقم بكسره أو مضغه أو سحقه.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول دائما الجرعة الكاملة التي وصفها طبيبك. لا تقم بتناول جزء من القرص فقط.</p><p>&nbsp;</p><p><strong>إذا تناولت اللاميراأكثر مما يجب:</strong></p><p>قم علي الفور بالاتصال بالطبيب أو الصيدلي، وقم بتقديم علبة اللاميرا لهم إن أمكن.</p><p>إذا قام شخص بتناول كميات كبيرة من اللاميرا من الممكن أن تظهر عليه أي من الأعراض الآتية:</p><p>&nbsp;- حركات عين سريعة لا يمكن السيطرة عليها (رأرأة).</p><p>- الحماقات وعدم التنسيق الحركي مما يؤثر علي التوازن (الترنح).</p><p>- تغيرات فى إيقاع القلب (والتى يمكن كشفها من خلال تخطيط القلب الكهربائى)</p><p>- فقدان الوعي أو الغيبوبة.</p><p>&nbsp;</p><p><strong>إذا نسيت تناول اللاميرا:</strong></p><p><strong>لا تقم بتناول جرعة مضاعفة لتعويض الجرعة الفائتة. قم فقط بتناول الجرعة القادمة في ميعادها المعتاد</strong></p><p><strong>&nbsp; قم باستشارة طبيبك عن كيفية بدء تناول العلاج من جديد. من المهم أن تقوم بذلك.&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p><strong>لا تتوقف عن تناول اللاميرا بدون الاستشارة</strong></p><p>يجب عليك تناول اللاميرا طالما نصح بها طبيبك. ولا تتوقف عن تناول الدواء إذا لم ينصح بهذا طبيبك.</p><p><strong>إذا كنت تتناول اللاميرا في الصرع</strong></p><p>للتوقف عن تناول اللاميرا<strong>، من المهم ان تقوم بتقليل الجرعة تدريجيا، </strong>علي مدار اسبوعين. إذا توقفت عن تناول اللاميرا فجأة، من الممكن أن تعود اليك حالة الصرع وربما أسوأ من قبل.</p><p><strong>إذا كنت تتناول اللاميرا في الاضطراب ثنائي القطب</strong></p><p>من الممكن أن يأخذ اللاميرا بعض الوقت لكي يعطي فاعلية، لذا من غير المرجح أن تشعر أنك أفضل علي الفور. إذا قمت بالتوقف عن تناول اللاميرا ، ليس من الضروري أن تقوم بتقليل الجرعة تدريجيا ولكن مازال يجب عليك استشارة طبيبك أولا، إذا كنت ترغب بالتوقف عن تناول اللاميرا<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p>مثل كل الأدوية قد يسبب هذا الدواء أعراض جانبية ولكنها لا تصيب كل من يتناوله.</p><p><strong>إذا حدث لك أي من الأعراض الجانبية التي تهدد الحياة: عليك أن تطلب مساعدة الطبيب علي الفور.</strong></p><p>عدد قليل ممن يتناولون اللاميرا قد يصابوا بأعراض جانبية تحسسية أو أعراض جلدية مهددة للحياة، والتي قد تتطور الي مشاكل أكثر خطورة إذا لم تعالج.</p><p>&nbsp;</p><p>تزيد فرص ظهور هذه الأعراض أثناء الشهور الأولي من العلاج باستخدام اللاميرا، وخاصة إذا كانت الجرعة الأولية جرعة عالية أو إذا قمت بزيادة الجرعة بطريقة سريعة أو إذا تناولت اللاميرا مع دواء أخر مثل الفالبروات. بعض هذهالأعراض أكثر شيوعا في الأطفال، لذا يتوجب علي الآباء الحرص علي متابعتهم.</p><p>الأعراض الناتجة عن هذه التفاعلات تشمل:</p><p>- الطفح الجلدي أو الإحمرار، والذي قد يتطور الي تفاعلات جلدية مهددة للحياة وتشمل الطفح الجلدي مع ظهور بثور علي نطاق واسع وتقشير الجلد، وتظهر خاصة حول الفم، الأنف، العيون والأعضاء التناسلية (متلازمة ستيفنز جونسون)، تقشير واسع في الجلد (أكثر من 30% من سطح الجلد- انحلال البشرة السمي).</p><p>- قرح الفم، الحنجرة، الأنف أو الأعضاء التناسلية.</p><p>- قرحة الفم أو احمر أو تورم العينين (التهاب الملتحمة).</p><p>- ارتفاع درجة الحرارة (الحمي)، أعراض تشبه الإنلونزا أو النعاس.</p><p>- تورم حول وجهك أو تورم الغدد في الرقبة، الإبط أو الفخذ.</p><p>- نزيف أو كدمات غير متوقعة، أو تحول الأصابع للون الأزرق.</p><p>- التهاب الحلق أو حدوث عدوي (مثل البرد) أكثر من المعتاد.</p><p>&nbsp;</p><p>في العديد من الحالات، تعتبر هذه الأعراض اشارات الي أثار جانبية أقل خطورة ولكن يجب عليك الاهتمام لأنها تعتبر مهددة للحياة ومن الممكن أن تتطور الي مشاكل أكثر جدية، مثل الفشل العضوي، إذا لم يتم علاجها. إذا قمت بملاحظة أي من هذه الأعراض:</p><p><strong>عليك التواصل مع الطبيب علي الفور</strong>. قد يقرر طبيبك أن تقوم بعمل تحاليل خاصة بالكبد، والكلي أو الدم ومن الممكن أن يخبرك بأن تتوقف عن تناول اللاميرا. في حالة اصابتك بحالة متقدمة من متلازمة ستيفنز جونسون أو انحلال البشرة السمي سوف يخبرك طبيبك أن عليك عدم استخدام اللاموتريجين مجددا نهائيا.</p><p>&nbsp;</p><p><strong>آثار جانبية شائعة جدا</strong>(من الممكن أن تؤثر في أكثر من 1 من كل 10 أشخاص)<strong>:</strong></p><p>- الصداع.</p><p>- الطفح الجلد.</p><p><strong>&nbsp;</strong></p><p><strong>آثار جانبية شائعة </strong>(من الممكن أن تؤثر في 1 من كل 10 أشخاص):</p><p>- العنف أو التهيج.</p><p>- الشعور بالنعاس.</p><p>- الشعور بالدوار.</p><p>- الإهتزاز أو الإرتعاش.</p><p>- صعوبة في النوم (الأرق).</p><p>- الشعور بالإرتباك.</p><p>- الإسهال.</p><p>- جفاف الفم.</p><p>- الشعور بالإعياء (الغثيان) أو يكون مريضا (التقيؤ).</p><p>- الشعور بالتعب.</p><p>&nbsp;- ألم في الظهر أو المفاصل، أو أي مكان أخر<strong>.</strong></p><p>&nbsp;</p><p><strong>آثار جانبية غير شائعة</strong> (من الممكن أن تؤثر في 1 من كل 100 شخص):</p><p>- الحماقات وعدم وجود تناسق حركي (ترنح).</p><p>&nbsp;- الرؤية المزدوجة أو عدم وضوح الرؤية<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>آثار جانبية نادرة </strong>(من الممكن أن تؤثر في 1 من كل 1000 شخص):</p><p>- تفاعلات جلدية مهددة للحياة (متلازمة ستيفنز جونسون): انظر أيضا المعلومات الموجودة في البداية في قسم 4.</p><p>- مجموعة من الأعراض معا وتشمل: الحمي، الغثيان، التقيؤ، الصداع، تصلب الرقبة و حساسية شديدة من الضوء الساطع. وقد يتسبب في ذلك التهاب الأغشية التي تغطي المخ والنخاع الشوكي (التهاب السحايا). تختفي هذه الأعراض بمجرد التوقف عن تناول الدواء ولكن في حالة استمرار هذه الأعراض أو سوء حالتها <strong>عليك التواصل مع</strong><strong> الطبيب.</strong></p><p>- حركات عين سريعة لا يمكن السيطرة عليها (رأرأة).</p><p>- حكة في العيون، مع افرازات وتيبس الجفون (التهاب الملتحمة).</p><p>&nbsp;</p><p><strong>أعراض جانبية نادرة جدا </strong>(من الممكن أن تؤثر في 1 من كل 10,000 شخص):</p><p>- تفاعلات جلدية مهددة للحياة (متلازمة ستيفنز جونسون): انظر أيضا المعلومات الموجودة في البداية في قسم 4.</p><p>- ارتفاع درجة الحرارة (الحمي): انظر أيضا المعلومات الموجودة في البداية في القسم 4.</p><p>- تورم حول الوجه (وذمة) أو تورم الغدد في الرقبة، الإبط أو الفخذ (اعتلال عقد لمفاوية): انظر أيضا المعلومات الموجودة في البداية في قسم 4.</p><p>- تغيرات في وظائف الكبد، والتي تظهر في تحاليل الدم، أو الفشل الكبدي: انظر أيضا المعلومات الموجودة في البداية في قسم 4.</p><p>- اضطراب تخثر الدم الخطير، الذي قد يسبب حالة نزيف أو كدمات غير متوقعة (تخثر الدم داخل الأوعية): انظر المعلومات الموجود في البداية في قسم 4.</p><p>- تغيرات تظهر في تحاليل الدم- تشمل انخفاض أعداد خلايا الدم الحمراء(فقر الدم)، انخفاض أعداد خلايا الدم البيضاء (نقص الكريات البيض، قلة العدلات، ندرة المحببات)، انخفاض أعداد الصفائح الدموية (الصفيحات)، انخفاض أعداد كل هذه الأنواع من الخلايا (قلة الكريات الشاملة) و اضطراب في نخاع العظام يسمي فقر الدم اللاتنسجي.</p><p>- الهلوسة (&quot;رؤية&quot; أو &quot;سماع&quot; الأشياء التي هي ليست موجودة في الحقيقة).</p><p>- الارتباك.</p><p>- الشعور &quot;بالتذبذب&quot; أو عدم الإستقرار عند التنقل.</p><p>- حركات للجسم لا يمكن السيطرة عليها (التشنجات اللاارادية)، تشنجات عضلية لا يمكن السيطرة عليها تؤثر علي العينين والرأس والجذع (كنع رقصي) أو غيرها من حركات الجسم غير العادية مثل الرجيج، الاهتزاز أو التصلب.</p><p>- في الأشخاص المصابين بالفعل بالصرع، تحدث النوبات معهم بشكل أكثر.</p><p>- في الأشخاص المصابين بالفعل بمرض باركنسون، تسوء الأعراض.</p><p>- التفاعلات الشبيهة بالذئبة ( قد تشمل الأعراض: آلام الظهر والمفاصل والتي في بعض الأحيان قد تكون مصحوبة بالحمي و/ أو تدهور الصحة العامة).</p><p>&nbsp;</p><p><strong>آثار جانبية أخري:</strong></p><p>قد تظهر أعراض جانبية أخري علي عدد قليل من الأشخاص ولكن نسبتهم بالتحديد غير معروفة:</p><p>- كانت هناك تقارير عن اضطرابات العظام بما في ذلك هشاشة وترقق العظام والكسور. استشر طبيبك أو الصيدلي إذا كنت تتناول علي مدي الطويل أدوية مضادة للصرع، لديك تاريخ من مرض هشاشة العظام أو تتناول المنشطات.</p><p>&nbsp;</p><p><strong>إذا كان لديك آثار جانبية</strong></p><p>&nbsp;&nbsp; إذا كان لديك آثار جانبية، قم باستشارة طبيبك أو الصيدلي. ويتضمن هذا أي أثار جانبية محتملة لم يتم ذكرها في هذه النشرة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول ورؤية الأطفال.</p><p>يحفظ في درجة حرارة أقل من 30&deg;C</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورعلىالشريط والعبوة.تاريخالانتهاءيشيرإلي اليومالأخيرمنكل شهر.</p><p>اللاميرا لا تتطلب ظروف خاصة للتخزين.</p><p>لاتتخلصمنأيأدويةعنطريقمياهالصرفالصحيأوالنفاياتالمنزلية. اسألالصيدلي عنكيفيةالتخلص منالأدويةالتيلمتعدتستخدم. وسوفتساعدهذهالتدابير عليحمايةالبيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي اللاموتريجين. كل قرص يحتوي علي 25 ملجم لاموتريجين.</p><p>المكونات الأخري هي: اللاكتوز بي بي 200، أفيسل بي اتش 101، بوفيدون 30، جليكولات صوديوم النشا، أكسيد الحديد الأصفر، مياه نقية، أفيسل بي اتش 102، ثاني أكسيد السيليكون الغروي، ستيرات المغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص اللاميرا 25 ملجم لونها أصفر، مستديرة، مسطحة الوجه، قرص غير مغطي مشطوف الحافة، محفور على أحد الجانبين &quot;37&quot; و عادية على الجانب الآخر. كل عبوة تحتوي علي 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             مارس 2019.   
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamira 25 mg Tablets
Lamira 50 mg Tablets
Lamira 100 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Lamira 25 mg tablet contains 25 mg lamotrigine.
Excipient: Each tablet contains 16 mg lactose.

Each Lamira 50 mg tablet contains 50 mg lamotrigine.
Excipient: Each tablet contains 32 mg lactose.

Each Lamira 100 mg tablet contains 100 mg lamotrigine.
Excipient: Each tablet contains 64 mg lactose.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
Lamira 25mg tablet are yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with "37"
on one side and plain on the other side.
Each unit carton contains 30 tablets.

Lamira 50mg tablets are yellow colour, round, flat face, beveled edge uncoated tablet, engraved with "38"
on one side and plain on the other side.
Each unit carton contains 30 tablets.

Lamira 100mg tablets are yellow colour, round, flat face, beveled edge uncoated tablet, engraved with
"39" on one side and plain on the other side.
A yellow colour, round, flat face, beveled edge uncoated tablet, plain on both sides.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Epilepsy </u></p><p><u>Adults and adolescents aged 13 years and above </u></p><p>- Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.</p><p>- Seizures associated with Lennox-Gastaut syndrome. Lamira is given as adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.</p><p><u>Children and adolescents aged 2 to 12 years</u></p><p>- Adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.</p><p>- Monotherapy of typical absence seizures.</p><p><u>Bipolar disorder </u></p><p><u>Adults aged 18 years and above </u></p><p>- Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes (see section 5.1).</p><p>Lamira is not indicated for the acute treatment of manic or depressive episodes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:730px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lamira tablets should be swallowed whole, and should not be chewed or crushed. If the calculated dose of lamotrigine (for example for treatment of children with epilepsy or patients with hepatic impairment) does not equate to whole tablets, the dose to be administered is that equal to the lower number of whole tablets.</p><p><u>Restarting therapy</u></p><p>Prescribers should assess the need for escalation to maintenance dose when restarting Lamira in patients who have discontinued Lamira for any reason, since the risk of serious rash is associated with high initial doses and exceeding the recommended dose escalation for lamotrigine (see section 4.4). The greater the&nbsp; interval of time since the previous dose, the more consideration should be given to escalation to the maintenance dose. When the interval since discontinuing lamotrigine exceeds five half-lives (see section 5.2), Lamira should generally be escalated to the maintenance dose according to the appropriate schedule. It is recommended that Lamira not be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk.</p><p><u>Epilepsy</u></p><p>The recommended dose escalation and maintenance doses for adults and adolescents aged 13 years and above (Table 1) and for children and adolescents aged 2 to 12 years (Table 2) are given below. Because of a risk of rash the initial dose and subsequent dose escalation should not be exceeded (see section 4.4). When concomitant AEDs are withdrawn or other AEDs/medicinal products are added on to treatment regimes containing lamotrigine, consideration should be given to the effect this may have on lamotrigine pharmacokinetics (see section 4.5).</p><p><em><u>Table 1: Adults and adolescents aged 13 years and above &ndash; recommended treatment regimen in epilepsy</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p>Treatment regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Usual maintenance dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>Monotherapy:</strong></p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved</p><p>500 mg/day has been required by some patients to achieve desired response</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong>&nbsp;(inhibitor of lamotrigineglucuronidation &ndash; see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>12.5 mg/day</p><p>(given as 25 mg on alternate days)</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 25 - 50 mg every one to two weeks until optimal response is achieved</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigineglucuronidation&nbsp;</strong>(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 - 400 mg/day</p><p>(two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 100 mg every one to two weeks until optimal response is achieved</p><p>700 mg/day has been required by some patients to achieve desired response</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigineglucuronidation</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved</p></td></tr><tr><td style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><em><u>Table 2: Children and adolescents aged 2 to 12 years - recommended treatment regimen in epilepsy (total daily dose in mg/kg body weight/day)</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p>Treatment regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Usual maintenance dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>Monotherapy of typical absence seizures:</strong></p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>1 &ndash; 15 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg/day every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200mg/day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong>&nbsp;(inhibitor of lamotrigineglucuronidation &ndash; see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any other concomitant medicinal products</p></td><td style="vertical-align:top"><p>0.15 mg/kg/day*</p><p>(once a day)</p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>1 - 5 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.3 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200 mg/day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>1.2 mg/kg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>5 - 15 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 1.2 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 400 mg/day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigineglucuronidation</p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>1 - 10 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg every one to two weeks until optimal response is achieved, with a maximum of maintenance dose of 200 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>* If the calculated daily dose in patients taking valproate is 1 mg or more but less than 2 mg, then Lamira 2 mg dispersible/chewable tablets may be taken on alternate days for the first two weeks. If the calculated daily dose in patients taking valproate is less than 1 mg, then Lamira should not be administered.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>To ensure a therapeutic dose is maintained the weight of a child must be monitored and the dose reviewed as weight changes occur. It is likely that patients aged two to six years will require a maintenance dose at the higher end of the recommended range.</p><p>If epileptic control is achieved with adjunctive treatment, concomitant AEDs may be withdrawn and patients continued on Lamiramonotherapy.</p><p><u>Children below 2 years</u></p><p>There are limited data on the efficacy and safety of lamotrigine for adjunctive therapy of partial seizures in children aged 1 month to 2 years (see section 4.4). There are no data in children below 1 month of age. Thus Lamira is not recommended for use in children below 2 years of age. If, based on clinical need, a decision to treat is nevertheless taken, see sections 4.4, 5.1 and 5.2.</p><p><u>Bipolar disorder</u></p><p>The recommended dose escalation and maintenance doses for adults of 18 years of age and above are given in the tables below. The transition regimen involves escalating the dose of lamotrigine to a maintenance stabilisation dose over six weeks (Table 3) after which other psychotropic medicinal products and/or AEDs can be withdrawn, if clinically indicated (Table 4). The dose adjustments following addition of other psychotropic medicinal products and/or AEDs are also provided below (Table 5). Because of the risk of rash the initial dose and subsequent dose escalation should not be exceeded (see section 4.4).</p><p><em><u>Table 3: Adults aged 18 years and above - recommended dose escalation to the maintenance total daily stabilisation dose in treatment of bipolar disorder</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Week 5</p></td><td style="vertical-align:top"><p>Target Stabilisation Dose (Week 6)*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Monotherapy with lamotrigine OR adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigineglucuronidation</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>200 mg/day - usual target dose for optimal response</p><p>(once a day or two divided doses)</p><p>Doses in the range 100 - 400 mg/day used in clinical trials</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong>&nbsp;(inhibitor of lamotrigineglucuronidation &ndash; see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>12.5 mg/day</p><p>(given as 25 mg on alternate days)</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg/day - usual target dose for optimal response</p><p>(once a day or two divided doses)</p><p>Maximum dose of 200 mg/day can be used depending on clinical response</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>300 mg/day in week 6, if necessary increasing to usual target dose of 400 mg/day in week 7, to achieve optimal response</p><p>(two divided doses)</p></td></tr><tr><td style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the dose escalation as recommended for lamotrigine with concurrent valproate, should be used.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* The Target stabilisation dose will alter depending on clinical response</p><p><em><u>Table 4: Adults aged 18 years and above - maintenance stabilisation total daily dose following withdrawal of concomitant&nbsp;medicinal products in treatment of bipolar disorder</u></em></p><p>Once the target daily maintenance stabilisation dose has been achieved, other medicinal products may be withdrawn as shown below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Current lamotriginestabilisation dose (prior to withdrawal)</p></td><td style="vertical-align:top"><p>Week 1 (beginning with withdrawal)</p></td><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>Week 3 onwards *</p></td></tr><tr><td style="vertical-align:top"><p><strong>Withdrawal of valproate</strong>&nbsp;(inhibitor of lamotrigineglucuronidation &ndash; see section 4.5), depending on original dose of lamotrigine<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>When valproate is withdrawn, double the stabilisation dose, not exceeding an increase of more than 100 mg/week</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (200 mg/day)</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (400 mg/day)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Withdrawal of inducers of lamotrigineglucuronidation&nbsp;</strong>(see section 4.5), depending on original dose of lamotrigine<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when the following are withdrawn:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>225 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Withdrawal of medicinal products that do NOT significantly inhibit or induce lamotrigineglucuronidation</strong>(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigineglucuronidation are withdrawn</p></td><td style="vertical-align:top"><p>Maintain target dose achieved in dose escalation (200 mg/day; two divided doses)</p><p>(dose range 100 - 400 mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen recommended for lamotrigine is to initially maintain the current dose and adjust the lamotrigine treatment based on clinical response .</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Dose may be increased to 400 mg/day as needed</p><p><em><u>Table 5: Adults aged 18 years and above - adjustment of lamotrigine daily dosing following the addition of other medicinal products in treatment of bipolar disorder</u></em></p><p>There is no clinical experience in adjusting the lamotrigine daily dose following the addition of other medicinal products. However, based on interaction studies with other medicinal products, the following recommendations can be made:</p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Current lamotriginestabilisation dose (prior to addition)</p></td><td style="vertical-align:top"><p>Week 1 (beginning with addition)</p></td><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>Week 3 onwards</p></td></tr><tr><td style="vertical-align:top"><p><strong>Addition of valproate</strong>&nbsp;(inhibitor of lamotrigineglucuronidation &ndash; see section 4.5), depending on original dose of lamotrigine<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when valproate is added regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (100 mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (150 mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (200 mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Addition of inducers of lamotrigineglucuronidation in patients NOT taking valproate</strong>&nbsp;(see section 4.5), depending on original dose of lamotrigine<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when the following are added without valproate:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>225 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Addition of medicinal products that do NOT significantly inhibit or induce lamotrigineglucuronidation</strong>&nbsp;(see section 4.5)<strong>:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigineglucuronidation are added</p></td><td style="vertical-align:top"><p>Maintain target dose achieved in dose escalation (200 mg/day; dose range 100-400 mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate, should be used.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><em><u>Discontinuation of Lamira in patients with bipolar disorder</u></em></p><p>In clinical trials, there was no increase in the incidence, severity or type of adverse reactions following abrupt termination of lamotrigine versus placebo. Therefore, patients may terminate Lamira without a step-wise reduction of dose.</p><p><em><u>Children and adolescents below 18 years</u></em></p><p>Lamira is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy (see section 4.4).</p><p><u>General dosing recommendations for Lamira in special patient populations</u></p><p><em><u>Women taking hormonal contraceptives</u></em></p><p>The use of an ethinyloestradiol/levonorgestrel (30 &mu;g/150 &mu;g) combination increases the clearance of lamotrigine by approximately two-fold, resulting in decreased lamotrigine levels. Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) may be needed to attain a maximal therapeutic response. During the pill-free week, a two-fold increase in lamotrigine levels has been observed. Dose-related adverse events cannot be excluded. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods; see sections 4.4 and 4.5).</p><p><em>Starting hormonal contraceptives in patients already taking maintenance doses of lamotrigine and NOT taking inducers of lamotrigineglucuronidation</em></p><p>The maintenance dose of lamotrigine will in most cases need to be increased by as much as two-fold (see sections 4.4 and 4.5). It is recommended that from the time that the hormonal contraceptive is started, the lamotrigine dose is increased by 50 to 100 mg/day every week, according to the individual clinical response. Dose increases should not exceed this rate, unless the clinical response supports larger increases. Measurement of serum lamotrigine concentrations before and after starting hormonal contraceptives may be considered, as confirmation that the baseline concentration of lamotrigine is being maintained. If necessary, the dose should be adapted. In women taking a hormonal contraceptive that includes one week of inactive treatment (&quot;pill-free week&quot;), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods; see sections 4.4 and 4.5).</p><p><em>Stopping hormonal contraceptives in patients already taking maintenance doses of lamotrigine and NOT taking inducers of lamotrigineglucuronidation</em></p><p>The maintenance dose of lamotrigine will in most cases need to be decreased by as much as 50% (see sections 4.4 and 4.5). It is recommended to gradually decrease the daily dose of lamotrigine by 50-100 mg each week (at a rate not exceeding 25% of the total daily dose per week) over a period of 3 weeks, unless the clinical response indicates otherwise. Measurement of serum lamotrigine concentrations before and after stopping hormonal contraceptives may be considered, as confirmation that the baseline concentration of lamotrigine is being maintained. In women who wish to stop taking a hormonal contraceptive that includes one week of inactive treatment (&quot;pill-free week&quot;), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. Samples for assessment of lamotrigine levels after permanently stopping the contraceptive pill should not be collected during the first week after stopping the pill.</p><p><em>Starting lamotrigine in patients already taking hormonal contraceptives</em></p><p>Dose escalation should follow the normal dose recommendation described in the tables.</p><p><em>Starting and stopping hormonal contraceptives in patients already taking maintenance doses of lamotrigine and TAKING inducers of lamotrigineglucuronidation</em></p><p>Adjustment to the recommended maintenance dose of lamotrigine may not be required.</p><p><em><u>Use with atazanavir/ritonavir</u></em></p><p>No adjustments to the recommended dose escalation of lamotrigine should be necessary when lamotrigine is added to the existing atazanavir/ritonavir therapy.</p><p>In patients already taking maintenance doses of lamotrigine and not taking glucuronidation inducers, the lamotrigine dose may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued. Plasma lamotrigine monitoring should be conducted before and during 2 weeks after starting or stopping atazanavir/ritonavir, in order to see if lamotrigine dose adjustment is needed (see section 4.5).</p><p><em><u>Use with lopinavir/ritonavir</u></em></p><p>No adjustments to the recommended dose escalation of lamotrigine should be necessary when lamotrigine is added to the existing lopinavir/ritonavir therapy.</p><p>In patients already taking maintenance doses of lamotrigine and not taking glucuronidation inducers, the lamotrigine dose may need to be increased if lopinavir/ritonavir is added, or decreased if lopinavir/ritonavir is discontinued. Plasma lamotrigine monitoring should be conducted before and during 2 weeks after starting or stopping lopinavir/ritonavir, in order to see if lamotrigine dose adjustment is needed (see section 4.5).</p><p><em><u>Elderly (above 65 years)</u></em></p><p>No dosage adjustment from the recommended schedule is required. The pharmacokinetics of lamotrigine in this age group do not differ significantly from a non-elderly adult population (see section 5.2).</p><p><em><u>Renal impairment</u></em></p><p>Caution should be exercised when administering Lamira to patients with renal failure. For patients with end-stage renal failure, initial doses of lamotrigine should be based on patients&#39; concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment (see sections 4.4 and 5.2).</p><p><em><u>Hepatic impairment</u></em></p><p>Initial, escalation and maintenance doses should generally be reduced by approximately 50% in patients with moderate (Child-Pugh grade B) and 75% in severe (Child-Pugh grade C) hepatic impairment. Escalation and maintenance doses should be adjusted according to clinical response (see section 5.2).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Haemophagocyticlymphohistiocytosis (HLH)</u></em></p><p>HLH has been reported in patients taking lamotrigine (see section 4.8). HLH is characterised by signs and symptoms, like fever, rash, neurological symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, high serum ferritin, hypertriglyceridaemia and abnormalities of liver function and coagulation. Symptoms occur generally within 4 weeks of treatment initiation, HLH can be life threatening. Patients should be informed of the symptoms associated with HLH and should be advised to seek medical attention immediately if they experience these symptoms while on lamotrigine therapy. Immediately evaluate patients who develop these signs and symptoms and consider a diagnosis of HLH. Lamotrigine should be promptly discontinued unless an alternative etiology can be established.</p><p>&nbsp;</p><p><em><u>Skin rash </u></em></p><p>There have been reports of adverse skin reactions, which have generally occurred within the first eight weeks after initiation of lamotrigine treatment. The majority of rashes are mild and self-limiting, however serious rashes requiring hospitalisation and discontinuation of lamotrigine have also been reported. These have included potentially life-threatening rashes such as Stevens&ndash;Johnson syndrome and toxic epidermal necrolysis (see section 4.8). In adults enrolled in studies utilizing the current lamotrigine dosing recommendations the incidence of serious skin rashes is approximately 1 in 500 in epilepsy patients. Approximately half of these cases have been reported as Stevens&ndash;Johnson syndrome (1 in 1000). In clinical trials in patients with bipolar disorder, the incidence of serious rash is approximately 1 in 1000. The risk of serious skin rashes in children is higher than in adults. Available data from a number of studies suggest the incidence of rashes associated with hospitalisation in epileptic children is from 1 in 300 to 1 in 100. In children, the initial presentation of a rash can be mistaken for an infection, physicians should consider the possibility of a reaction to lamotrigine treatment in children that develop symptoms of rash and fever during the first eight weeks of therapy. Additionally the overall risk of rash appears to be strongly associated with: - high initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy (see section 4.2) - concomitant use of valproate (see section 4.2). Caution is also required when treating patients with a history of allergy or rash to other AEDs as the frequency of non-serious rash after treatment with lamotrigine was approximately three times higher in these patients than in those without such history. All patients (adults and children) who develop a rash should be promptly evaluated and Lamira withdrawn immediately unless the rash is clearly not related to lamotrigine treatment. It is recommended that Lamiranot be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk. If the patient has developed SJS or TEN with the use of lamotrigine, treatment with lamotrigine must not be restarted in this patient at any time .</p><p>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema, abnormalities of the blood and liver and aseptic meningitis (see section 4.8). The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation and multiorgan failure. It is important to note that early manifestations of hypersensitivity (for example fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present the patient should be evaluated immediately and Lamira discontinued if an alternative aetiology cannot be established. Aseptic meningitis was reversible on withdrawal of the drug in most cases, but recurred in a number of cases on re-exposure to lamotrigine. Re-exposure resulted in a rapid return of symptoms that were frequently more severe. Lamotrigine should not be restarted in patients who have discontinued due to aseptic meningitis associated with prior treatment of lamotrigine.</p><p>&nbsp;</p><p><u>Clinical worsening and suicide risk</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with AEDs in several indications. A meta-analysis of randomised placebo-controlled trials of AEDs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lamotrigine. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. In patients with bipolar disorder, worsening of depressive symptoms and/or the emergence of suicidality may occur whether or not they are taking medications for bipolar disorder, including Lamira. Therefore patients receiving Lamira for bipolar disorder should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes. Certain patients, such as those with a history of suicidal behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, may be at a greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient&#39;s presenting symptoms.</p><p>&nbsp;</p><p><em><u>Hormonal contraceptives</u></em></p><p><em><u>Effects of hormonal contraceptives on lamotrigine efficacy</u></em></p><p>The use of an ethinyloestradiol/levonorgestrel (30 &mu;g/150 &mu;g) combination increases the clearance of lamotrigine by approximately two-fold resulting in decreased lamotrigine levels (see section 4.5). A decrease in lamotrigine levels has been associated with loss of seizure control. Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) will be needed in most cases to attain a maximal therapeutic response. When stopping hormonal contraceptives, the clearance of lamotrigine may be halved. Increases in lamotrigine concentrations may be associated with dose-related adverse events. Patients should be monitored with respect to this.</p><p>In women not already taking an inducer of lamotrigineglucuronidation and taking a hormonal contraceptive that includes one week of inactive treatment (for example &quot;pill-free week&quot;), gradual transient increases in lamotrigine levels will occur during the week of inactive treatment (see section 4.2). Variations in lamotrigine levels of this order may be associated with adverse effects. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods). The interaction between other oral contraceptive or HRT treatments and lamotrigine have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters.</p><p>&nbsp;</p><p><em><u>Effects of lamotrigine on hormonal contraceptive efficacy </u></em></p><p>An interaction study in 16 healthy volunteers has shown that when lamotrigine and a hormonal contraceptive (ethinyloestradiol/levonorgestrel combination) are administered in combination, there is a modest increase in levonorgestrel clearance and changes in serum FSH and LH (see section 4.5). The impact of these changes on ovarian ovulatory activity is unknown. However, the possibility of these changes resulting in decreased contraceptive efficacy in some patients taking hormonal preparations with lamotrigine cannot be excluded. Therefore patients should be instructed to promptly report changes in their menstrual pattern, i.e. breakthrough bleeding.</p><p><em><u>Dihydrofolatereductase</u></em></p><p>Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase, hence there is a possibility of interference with folate metabolism during long-term therapy (see section 4.6). However, during prolonged human dosing, lamotrigine did not induce significant changes in the haemoglobin concentration, mean corpuscular volume, or serum or red blood cell folate concentrations up to 1 year or red blood cell folate concentrations for up to 5 years.</p><p><u><em>Renal failure</em></u></p><p>In single dose studies in subjects with end stage renal failure, plasma concentrations of lamotrigine were not significantly altered. However, accumulation of the glucuronide metabolite is to be expected; caution should therefore be exercised in treating patients with renal failure.</p><p><em><u>Patients taking other preparations containing lamotrigine </u></em></p><p>Lamira should not be administered to patients currently being treated with any other preparation containing lamotrigine without consulting a doctor.</p><p><u><em>Brugada-type ECG </em></u></p><p>Arrhythmogenic ST-T abnormality and typical Brugada ECG pattern has been reported in patients treated with lamotrigine. The use of lamotrigine should be carefully considered in patients with Brugada syndrome.</p><p>25, 50, and 100 mg tablets: Excipient of Lamira tablets Lamira tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactosemalabsorption should not take this medicine.</p><p>&nbsp;</p><p><u><em>Development in children</em> </u></p><p>There are no data on the effect of lamotrigine on growth, sexual maturation and cognitive, emotional and behavioural developments in children.</p><p><em><u>Precautions relating to epilepsy </u></em></p><p>As with other AEDs, abrupt withdrawal of Lamira may provoke rebound seizures. Unless safety concerns (for example rash) require an abrupt withdrawal, the dose of Lamira should be gradually decreased over a period of two weeks. There are reports in the literature that severe convulsive seizures including status epilepticus may lead to rhabdomyolysis, multiorgan dysfunction and disseminated intravascular coagulation, sometimes with fatal outcome. Similar cases have occurred in association with the use of lamotrigine. A clinically significant worsening of seizure frequency instead of an improvement may be observed. In patients with more than one seizure type, the observed benefit of control for one seizure type should be weighed against any observed worsening in another seizure type. Myoclonic seizures may be worsened by lamotrigine. There is a suggestion in the data that responses in combination with enzyme inducers is less than in combination with non-enzyme inducing antiepileptic agents. The reason is unclear. In children taking lamotrigine for the treatment of typical absence seizures, efficacy may not be maintained in all patients.</p><p><u><em>Precautions relating to bipolar disorde</em></u>r</p><p><u>Children and adolescents below 18 years</u></p><p>Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:730px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction studies have only been performed in adults.</p><p>UDP-glucuronyltransferases have been identified as the enzymes responsible for metabolism of lamotrigine. There is no evidence that lamotrigine causes clinically significant induction or inhibition of hepatic oxidative drug-metabolising enzymes, and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur. Lamotrigine may induce its own metabolism but the effect is modest and unlikely to have significant clinical consequences.</p><p><em><u>Table 6: Effects of other medicinal products on glucuronidation of lamotrigine</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products that significantly inhibit glucuronidation of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Medicinal products that significantly induce glucuronidation of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Medicinal products that do not significantly inhibit or induce glucuronidation of lamotrigine</strong></p></td></tr><tr><td style="vertical-align:top"><p>Valproate</p></td><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Oxcarbazepine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Felbamate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenobarbitone</p></td><td style="vertical-align:top"><p>Gabapentin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Primidone</p></td><td style="vertical-align:top"><p>Levetiracetam</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rifampicin</p></td><td style="vertical-align:top"><p>Pregabalin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>Topiramate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ethinyloestradiol/ levonorgestrel combination**</p></td><td style="vertical-align:top"><p>Zonisamide</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atazanavir/ritonavir*</p></td><td style="vertical-align:top"><p>Lithium</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Buproprion</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Olanzapine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aripiprazole</p></td></tr></tbody></table><p>*For dosing guidance (see section 4.2)</p><p>**Other oral contraceptive and HRT treatments have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u><em>Interactions involving antiepileptic drugs</em></u></p><p>Valproate, which inhibits the glucuronidation of lamotrigine, reduces the metabolism of lamotrigine and increases the mean half-life of lamotrigine nearly two-fold. In patients receiving concomitant therapy with valproate, the appropriate treatment regimen should be used (see section 4.2). Certain AEDs (such as phenytoin, carbamazepine, phenobarbitone and primidone) which induce hepatic drug-metabolising enzymes induce the glucuronidation of lamotrigine and enhance the metabolism of lamotrigine. In patients receiving concomitant therapy with phenytoin, carbamazepine, pheonbarbitone or primidone, the appropriate treatment regimen should be used (see section 4.2). There have been reports of central nervous system events including dizziness, ataxia, diplopia, blurred vision and nausea in patients taking carbamazepine following the introduction of lamotrigine. These events usually resolve when the dose of carbamazepine is reduced. A similar effect was seen during a study of lamotrigine and oxcarbazepine in healthy adult volunteers, but dose reduction was not investigated. There are reports in the literature of decreased lamotrigine levels when lamotrigine was given in combination with oxcarbazepine. However, in a prospective study in healthy adult volunteers using doses of 200 mg lamotrigine and 1200 mg oxcarbazepine, oxcarbazepine did not alter the metabolism of lamotrigine and lamotrigine did not alter the metabolism of oxcarbazepine. Therefore in patients receiving concomitant therapy with oxcarbazepine, the treatment regimen for lamotrigine adjunctive therapy without valproate and without inducers of lamotrigineglucuronidation should be used (see section 4.2). In a study of healthy volunteers, coadministration of felbamate (1200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.</p><p>&nbsp;</p><p>Based on a retrospective analysis of plasma levels in patients who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine. Potential interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine. Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg, 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin. Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations. In a study of patients with epilepsy, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day) for 35 days had no significant effect on the pharmacokinetics of lamotrigine. Although changes in the plasma concentrations of other AEDs have been reported, controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant AEDs. Evidence from in vitro studies indicates that lamotrigine does not displace other AEDs from protein binding sites.</p><p>&nbsp;</p><p><u><em>Interactions involving other psychoactive agents</em></u></p><p>The pharmacokinetics of lithium after 2 g of anhydrous lithium gluconate given twice daily for six days to 20 healthy subjects were not altered by co-administration of 100 mg/day lamotrigine. Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of lamotrigine in 12 subjects and had only a slight increase in the AUC of lamotrigineglucuronide. In a study in healthy adult volunteers, 15 mg olanzapine reduced the AUC and Cmax of lamotrigine by an average of 24% and 20%, respectively. An effect of this magnitude is not generally expected to be clinically relevant. Lamotrigine at 200 mg did not affect the pharmacokinetics of olanzapine. Multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single dose pharmacokinetics of 2 mg risperidone in 14 healthy adult volunteers. Following the co-administration of risperidone 2 mg with lamotrigine, 12 out of the 14 volunteers reported somnolence compared to 1 out of 20 when risperidone was given alone, and none when lamotrigine was administered alone. In a study of 18 adult patients with bipolar I disorder, receiving an established regimen of lamotrigine (100-400 mg/day), doses of aripiprazole were increased from 10 mg/day to a target of 30 mg/day over a 7 day period and continued once daily for a further 7 days. An average reduction of approximately 10% in Cmax and AUC of lamotrigine was observed. An effect of this magnitude is not expected to be of clinical consequence. In vitro experiments indicated that the formation of lamotrigine&#39;s primary metabolite, the 2-Nglucuronide, was minimally inhibited by co-incubation with amitriptyline, bupropion, clonazepam, haloperidol or lorazepam. These experiments also suggested that metabolism of lamotrigine was unlikely to be inhibited by clozapine, fluoxetine, phenelzine, risperidone, sertraline or trazodone. In addition, a&nbsp;study of bufuralol metabolism using human liver microsome preparations suggested that lamotrigine would not reduce the clearance of medicinal products metabolised predominantly by CYP2D6.</p><p>&nbsp;</p><p><em><u>Interactions involving hormonal contraceptives </u></em></p><p><em><u>Effect of hormonal contraceptives on lamotrigine pharmacokinetics</u></em></p><p>In a study of 16 female volunteers, dosing with 30 &mu;gethinyloestradiol/150 &mu;glevonorgestrel in a combined oral contraceptive pill caused an approximately two-fold increase in lamotrigine oral clearance, resulting in an average 52% and 39% reduction in lamotrigine AUC and Cmax, respectively. Serum lamotrigine concentrations increased during the course of the week of inactive treatment (including the &quot;pill-free&quot; week), with pre-dose concentrations at the end of the week of inactive treatment being, on average, approximately two-fold higher than during co-therapy (see section 4.4). No adjustments to the recommended dose escalation guidelines for lamotrigine should be necessary solely based on the use of hormonal contraceptives, but the maintenance dose of lamotrigine will need to be increased or decreased in most cases when starting or stopping hormonal contraceptives (see section 4.2).</p><p>&nbsp;</p><p><em><u>Effect of lamotrigine on hormonal contraceptive pharmacokinetics</u></em></p><p>In a study of 16 female volunteers, a steady state dose of 300 mg lamotrigine had no effect on the pharmacokinetics of the ethinyloestradiol component of a combined oral contraceptive pill. A modest increase in oral clearance of the levonorgestrel component was observed, resulting in an average 19% and 12% reduction in levonorgestrel AUC and Cmax, respectively. Measurement of serum FSH, LH and oestradiol during the study indicated some loss of suppression of ovarian hormonal activity in some women, although measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 subjects. The impact of the modest increase in levonorgestrelclearance, and the changes in serum FSH and LH, on ovarian ovulatory activity is unknown (see section 4.4). The effects of doses of lamotrigine other than 300 mg/day have not been studied and studies with other female hormonal preparations have not been conducted.</p><p><em><u>Interactions involving other medicinal products</u></em></p><p>In a study in 10 male volunteers, rifampicin increased lamotrigine clearance and decreased lamotrigine half-life due to induction of the hepatic enzymes responsible for glucuronidation. In patients receiving concomitant therapy with rifampicin, the appropriate treatment regimen should be used (see section 4.2). In a study in healthy volunteers, lopinavir/ritonavir approximately halved the plasma concentrations of lamotrigine, probably by induction of glucuronidation. In patients receiving concomitant therapy with lopinavir/ritonavir, the appropriate treatment regimen should be used (see section 4.2). In a study in healthy adult volunteers, atazanavir/ritonavir (300 mg/100 mg) administered for 9 days reduced the plasma AUC and Cmax of lamotrigine (single 100 mg dose) by an average of 32% and 6%, respectively. In patients receiving concomitant therapy with atazanavir/ritonavir, the appropriate treatment regimen should be used (see section 4.2). Data from in vitro assessment demonstrate that lamotrigine, but not the N(2)-glucuronide metabolite, is an inhibitor of OCT 2 at potentially clinically relevant concentrations. These data demonstrate that lamotrigine is a more potent in vitroinhibitor of OCT 2 than cimetidine, with IC50 values of 53.8 &micro;M and 186 &micro;M, respectively. Co-administration of lamotrigine with renally excreted medicinal products which are substrates of OCT2 (e.g. metformin, gabapentin and varenicline) may result in increased plasma levels of these drugs.</p><p>&nbsp;The clinical significance of this has not been clearly defined, however care should be taken in patients coadministered with these medicinal products.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Risk related to antiepileptic drugs in general</u></em></p><p>Specialist advice should be given to women who are of childbearing potential. The need for treatment with AEDs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of AED therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with AEDs compared with the expected incidence in the general population of approximately 3%. The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects. Therapy with multiple AEDs is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible.</p><p><em><u>Risk related to lamotrigine</u></em></p><p><em><u>Pregnancy</u></em></p><p>Postmarketing data from several prospective pregnancy registries have documented outcomes in over 2000 women exposed to lamotrigine monotherapy during the first trimester of pregnancy. Overall, these data do not suggest a substantial increase in the risk for major congenital malformations, although data are still too limited to exclude a moderate increase in the risk of oral clefts. Animal studies have shown developmental toxicity (see section 5.3). If therapy with Lamira is considered necessary during pregnancy, the lowest possible therapeutic dose is recommended. Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase and could therefore theoretically lead to an increased risk of embryofoetal damage by reducing folic acid levels (see section 4.4). Intake of folic acid when planning pregnancy and during early pregnancy may be considered. Physiological changes during pregnancy may affect lamotrigine levels and/or therapeutic effect. There have been reports of decreased lamotrigine plasma levels during pregnancy with a potential risk of loss of seizure control. After birth lamotrigine levels may increase rapidly with a risk of dose-related adverse events. Therefore lamotrigine serum concentrations should be monitored before, during and after pregnancy, as well as shortly after birth. If necessary, the dose should be adapted to maintain the lamotrigine serum concentration at the same level as before pregnancy, or adapted according to clinical response. In addition, dose-related undesirable effects should be monitored after birth.</p><p>Pregnancy Category C</p><p><em><u>Lactation</u></em></p><p>Lamotrigine has been reported to pass into breast milk in highly variable concentrations, resulting in total lamotrigine levels in infants of up to approximately 50% of the mother&#39;s. Therefore, in some breast-fed infants, serum concentrations of lamotrigine may reach levels at which pharmacological effects occur. Among a limited group of exposed infants, no adverse effects were observed.</p><p>The potential benefits of breast-feeding should be weighed against the potential risk of adverse effects occurring in the infant. Should a woman decide to breast-feed while on therapy with lamotrigine, the infant should be monitored for adverse effects.</p><p><em><u>Fertility</u></em></p><p>Animal experiments did not reveal impairment of fertility by lamotrigine (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As there is individual variation in response to all AED therapy, patients taking Lamira to treat epilepsy should consult their physician on the specific issues of driving and epilepsy. No studies on the effects on the ability to drive and use machines have been performed. Two volunteer studies have demonstrated that the effect of lamotrigine on fine visual motor co-ordination, eye movements, body sway and subjective sedative effects did not differ from placebo. In clinical trials with lamotrigine adverse reactions of a neurological character such as dizziness and diplopia have been reported. Therefore, patients should see how Lamira therapy affects them before driving or operating machinery</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:730px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>The undesirable effects for epilepsy and bipolar disorder indications are based on available data from controlled clinical studies and other clinical experience and are listed in the table below. Frequency categories are derived from controlled clinical studies (epilepsy monotherapy (identified by<sup>&dagger;</sup>) and bipolar disorder (identified by&nbsp;<sup>&sect;</sup>)). Where frequency categories differ between clinical trial data from epilepsy and bipolar disorder the most conservative frequency is shown. However, where no controlled clinical trial data are available, frequency categories have been obtained from other clinical experience.</p><p>.</p><p>The following convention has been utilised for the classification of undesirable effects:- Very common (<u>&gt;</u>1/10); common (<u>&gt;</u>1/100 to &lt;1/10); uncommon (<u>&gt;</u>1/1000 to &lt;1/100); rare (<u>&gt;</u>1/10,000 to &lt;1/1000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Haematological abnormalities<sup>1</sup>&nbsp;including neutropenia, leucopenia, anaemia, thrombocytopenia, pancytopenia, aplastic anaemia, agranulocytosis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lymphadenopathy<sup>1</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity syndrome<sup>2&nbsp;</sup>(including such symptoms as, fever, lymphadenopathy, facial oedema, abnormalities of the blood and liver, disseminated intravascular coagulation, multi organ failure).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Aggression, irritability</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusion, hallucinations, tics</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Headache<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence<sup>&dagger;&sect;</sup>, dizziness<sup>&dagger;&sect;</sup>, tremor<sup>&dagger;</sup>, insomnia<sup>&dagger;</sup>&nbsp;agitation<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ataxia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nystagmus<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Unsteadiness, movement disorders, worsening of Parkinson&#39;s disease&nbsp;<sup>3</sup>, extrapyramidal effects, choreoathetosis<sup>&dagger;</sup>, increase in seizure frequency</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aseptic meningitis (see section 4.4)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Diplopia<sup>&dagger;</sup>, blurred vision<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea<sup>&dagger;</sup>, vomiting<sup>&dagger;</sup>, diarrhoea<sup>&dagger;</sup>, dry mouth<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatic dysfunction<sup>4</sup>, increased liver function tests</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Skin rash<sup>5&dagger;&sect;</sup></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens&ndash;Johnson Syndrome<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lupus-like reactions</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Tiredness<sup>&dagger;</sup>, pain<sup>&sect;</sup>, back pain<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><sup>1&nbsp;</sup>Haematological abnormalities and lymphadenopathy may or may not be associated with the hypersensitivity syndrome (see Immune system disorders).</p><p><sup>2&nbsp;</sup>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema and abnormalities of the blood and liver. The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation and multiorgan failure. It is important to note that early manifestations of hypersensitivity (for example fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present, the patient should be evaluated immediately and Lamira discontinued if an alternative aetiology cannot be established.</p><p><sup>3&nbsp;</sup>These effects have been reported during other clinical experience.</p><p>There have been reports that lamotrigine may worsen parkinsonian symptoms in patients with pre-existing Parkinson&#39;s disease, and isolated reports of extrapyramidal effects and choreoathetosis in patients without this underlying condition.</p><p><sup>4&nbsp;</sup>Hepatic dysfunction usually occurs in association with hypersensitivity reactions but isolated cases have been reported without overt signs of hypersensitivity.</p><p><sup>5&nbsp;</sup>In clinical trials in adults, skin rashes occurred in up to 8-12% of patients taking lamotrigine and in 5-6% of patients taking placebo. The skin rashes led to the withdrawal of lamotrigine treatment in 2% of patients. The rash, usually macropapular in appearance, generally appears within eight weeks of starting treatment and resolves on withdrawal of Lamira (see Section 4.4).</p><p>Serious potentially life-threatening skin rashes, including Stevens&ndash;Johnson syndrome and toxic epidermal necrolysis (Lyell&#39;s Syndrome) have been reported. Although the majority recover on withdrawal of lamotrigine treatment, some patients experience irreversible scarring and there have been rare cases of associated death (see section 4.4).</p><p>The overall risk of rash, appears to be strongly associated with:</p><p>- high initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy (see section 4.2)</p><p>- concomitant use of valproate (see section 4.2).</p><p>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms (see Immune system disorders).</p><p>There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with lamotrigine. The mechanism by which lamotrigine affects bone metabolism has not been identified.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" align="right" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>To report any side effect(s):</strong></p><p style="text-align:center"><strong>Saudi Arabia&nbsp;</strong></p><p style="text-align:center">□ The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="text-align:center">o Fax: +966-11-205-7662</p><p style="text-align:center">o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:center">o Reporting hotline: 19999</p><p style="text-align:center">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:center">o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Symptoms and signs</u></em></p><p>Acute ingestion of doses in excess of 10 to 20 times the maximum therapeutic dose has been reported. Overdose has resulted in symptoms including nystagmus, ataxia, impaired consciousness and coma</p><p><em><u>Treatment</u></em></p><p>In the event of overdose, the patient should be admitted to hospital and given appropriate supportive therapy. Therapy aimed at decreasing absorption (activated charcoal) should be performed if indicated. Further management should be as clinically indicated. There is no experience with haemodialysis as treatment of overdose. In six volunteers with kidney failure, 20% of the lamotrigine was removed from the body during a 4-hour haemodialysis session (see section 5.2)..</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:730px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pharmacotherapeutic group: other antiepileptics, ATC code: <strong>N03AX09</strong>.</p><p><em><u>Mechanism of action</u></em></p><p>The results of pharmacological studies suggest that lamotrigine is a use- and voltage-dependent blocker of voltage gated sodium channels. It inhibits sustained repetitive firing of neurones and inhibits release of glutamate (the neurotransmitter which plays a key role in the generation of epileptic seizures). These effects are likely to contribute to the anticonvulsant properties of lamotrigine. In contrast, the mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established, although interaction with voltage gated sodium channels is likely to be important.</p><p><u><em>Pharmacodynamic effects </em></u></p><p>In tests designed to evaluate the central nervous system effects of medicinal products, the results obtained using doses of 240 mg lamotrigine administered to healthy volunteers did not differ from placebo, whereas both 1000 mg phenytoin and 10 mg diazepam each significantly impaired fine visual motor coordination and eye movements, increased body sway and produced subjective sedative effects. In another study, single oral doses of 600 mg carbamazepine significantly impaired fine visual motor coordination and eye movements, while increasing both body sway and heart rate, whereas results with lamotrigine at doses of 150 mg and 300 mg did not differ from placebo.</p><p><em><u>Clinical efficacy and safety in children aged 1 to 24 months </u></em></p><p>The efficacy and safety of adjunctive therapy in partial seizures in patients aged 1 to 24 months has been evaluated in a small double-blind placebo-controlled withdrawal study. Treatment was initiated in 177 subjects, with a dose titration schedule similar to that of children aged 2 to 12 years. Lamotrigine 2 mg tablets are the lowest strength available, therefore the standard dosing schedule was adapted in some cases during the titration phase (for example, by administering a 2 mg tablet on alternate days when the calculated dose was less than 2 mg). Serum levels were measured at the end of week 2 of titration and the subsequent dose either reduced or not increased if the concentration exceeded 0.41 &micro;g/mL, the expected concentration in adults at this time point. Dose reductions of up to 90% were required in some patients at the end of week 2. Thirty-eight responders (&gt; 40% decrease in seizure frequency) were randomised to placebo or continuation of lamotrigine. The proportion of subjects with treatment failure was 84% (16/19 subjects) in the placebo arm and 58% (11/19 subjects) in the lamotrigine arm. The difference was not statistically significant: 26.3%, CI95% -2.6% &lt;&gt; 50.2%, p=0.07. A total of 256 subjects between 1 to 24 months of age have been exposed to lamotrigine in the dose range 1 to 15 mg/kg/day for up to 72 weeks. The safety profile of lamotrigine in children aged 1 month to 2&nbsp;years was similar to that in older children except that clinically significant worsening of seizures (&gt;=50%) was reported more often in children under 2 years of age (26%) as compared to older children (14%).</p><p><u><em>Clinical efficacy and safety in Lennox-Gastaut syndrome</em></u></p><p>There are no data for monotherapy in seizures associated with Lennox-Gastaut syndrome.</p><p><em><u>Clinical efficacy in the prevention of mood episodes in patients with bipolar disorder</u></em></p><p>The efficacy of lamotrigine in the prevention of mood episodes in patients with bipolar I disorder has been evaluated in two studies. Study SCAB2003 was a multicentre, double-blind, double dummy, placebo and lithium-controlled, randomised fixed dose evaluation of the long-term prevention of relapse and recurrence of depression and/or mania in patients with bipolar I disorder who had recently or were currently experiencing a major depressive episode. Once stabilised using lamotriginemonotherapy or adjunctive therapy, patients were randomly assigned into one of five treatment groups: lamotrigine (50, 200, 400 mg/day), lithium (serum levels of 0.8 to 1.1 mMol/L) or placebo for a maximum of 76 weeks (18 months). The primary endpoint was &quot;Time to Intervention for a Mood Episode (TIME)&quot;, where the interventions were additional pharmacotherapy or electroconvulsive therapy (ECT). Study SCAB2006 had a similar design as study SCAB2003, but differed from study SCAB2003 in evaluating a flexible dose of lamotrigine (100 to 400 mg/day) and including patients with bipolar I disorder who had recently or were currently experiencing a manic episode. The results are shown in Table 7.</p><p><em><u>Table 7: Summary of results from studies investigating the efficacy of lamotrigine in the prevention of mood episodes in patients with bipolar I disorder</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td style="vertical-align:top"><p><strong>&#39;Proportion&#39; of patients being event free at week 76</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Study SCAB2003</strong></p><p><strong>Bipolar I</strong></p></td><td style="vertical-align:top"><p><strong>Study SCAB2006</strong></p><p><strong>Bipolar I</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Inclusion criterion</p></td><td style="vertical-align:top"><p>Major depressive episode</p></td><td style="vertical-align:top"><p>Major manic episode</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lamotrigine</p></td><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Lamotrigine</p></td><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>Intervention free</p></td><td style="vertical-align:top"><p>0.22</p></td><td style="vertical-align:top"><p>0.21</p></td><td style="vertical-align:top"><p>0.12</p></td><td style="vertical-align:top"><p>0.17</p></td><td style="vertical-align:top"><p>0.24</p></td><td style="vertical-align:top"><p>0.04</p></td></tr><tr><td style="vertical-align:top"><p>p-value Log rank test</p></td><td style="vertical-align:top"><p>0.004</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Depression free</p></td><td style="vertical-align:top"><p>0.51</p></td><td style="vertical-align:top"><p>0.46</p></td><td style="vertical-align:top"><p>0.41</p></td><td style="vertical-align:top"><p>0.82</p></td><td style="vertical-align:top"><p>0.71</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>p-value Log rank test</p></td><td style="vertical-align:top"><p>0.047</p></td><td style="vertical-align:top"><p>0.209</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.167</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Free of mania</p></td><td style="vertical-align:top"><p>0.70</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>0.67</p></td><td style="vertical-align:top"><p>0.53</p></td><td style="vertical-align:top"><p>0.64</p></td><td style="vertical-align:top"><p>0.37</p></td></tr><tr><td style="vertical-align:top"><p>p-value Log rank test</p></td><td style="vertical-align:top"><p>0.339</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.280</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p>In supportive analyses of time to first depressive episode and time to first manic/hypomanic or mixed episode, the lamotrigine-treated patients had significantly longer times to first depressive episode than placebo patients, and the treatment difference with respect to time to manic/hypomanic or mixed episodes was not statistically significant.</p><p>The efficacy of lamotrigine in combination with mood stabilisers has not been adequately studied.</p><p><u>Study of the effect of lamotrigine on cardiac conduction</u></p><p>A study in healthy adult volunteers evaluated the effect of repeat doses of lamotrigine (up to 400 mg/day) on cardiac conduction, as assessed by 12-lead ECG. There was no clinically significant effect of lamotrigine on QT interval compared to placebo.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption</u></em></p><p>Lamotrigine is rapidly and completely absorbed from the gut with no significant first-pass metabolism. Peak plasma concentrations occur approximately 2.5 hours after oral administration of lamotrigine. Time to maximum concentration is slightly delayed after food but the extent of absorption is unaffected. There is considerable inter-individual variation in steady state maximum concentrations but within an individual, concentrations rarely vary.</p><p><u><em>Distribution</em></u></p><p>Binding to plasma proteins is about 55%; it is very unlikely that displacement from plasma proteins would result in toxicity. The volume of distribution is 0.92 to 1.22 L/kg.</p><p><em><u>Biotransformation</u></em></p><p>UDP-glucuronyltransferases have been identified as the enzymes responsible for metabolism of lamotrigine. Lamotrigine induces its own metabolism to a modest extent depending on dose. However, there is no evidence that lamotrigine affects the pharmacokinetics of other AEDs and data suggest that interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur.</p><p><u><em>Elimination</em></u></p><p>The apparent plasma clearance in healthy subjects is approximately 30 mL/min. Clearance of lamotrigine is primarily metabolic with subsequent elimination of glucuronide-conjugated material in urine. Less than 10% is excreted unchanged in the urine. Only about 2% of lamotrigine-related material is excreted in faeces. Clearance and half-life are independent of dose. The apparent plasma half-life in healthy subjects is estimated to be approximately 33 hours (range 14 to 103 hours). In a study of subjects with Gilbert&#39;s Syndrome, mean apparent clearance was reduced by 32% compared with normal controls but the values are within the range for the general population. The half-life of lamotrigine is greatly affected by concomitant medicinal products. Mean half-life is reduced to approximately 14 hours when given with glucuronidation-inducing medicinal products such as&nbsp;carbamazepine and phenytoin and is increased to a mean of approximately 70 hours when coadministered with valproate alone (see section 4.2).</p><p><em><u>Linearity</u></em></p><p>The pharmacokinetics of lamotrigineare linear up to 450 mg, the highest single dose tested.</p><p><em><u>Special patient populations </u></em></p><p><u><em>Children</em></u></p><p>Clearance adjusted for body weight is higher in children than in adults with the highest values in children under five years. The half-life of lamotrigine is generally shorter in children than in adults with a mean value of approximately 7 hours when given with enzyme-inducing medicinal products such as carbamazepine and phenytoin and increasing to mean values of 45 to 50 hours when co-administered with valproate alone (see section 4.2).</p><p><em><u>Infants aged 2 to 26 months </u></em></p><p>In 143 paediatric patients aged 2 to 26 months, weighing 3 to 16 kg, clearance was reduced compared to older children with the same body weight, receiving similar oral doses per kg body weight as children older than 2 years. The mean half-life was estimated at 23 hours in infants younger than 26 months on enzyme-inducing therapy, 136 hours when co-administered with valproate and 38 hours in subjects treated without enzyme inducers/inhibitors. The inter-individual variability for oral clearance was high in the group of paediatric patients of 2 to 26 months (47%). The predicted serum concentration levels in children of 2 to 26 months were in general in the same range as those in older children, though higher Cmax levels are likely to be observed in some children with a body weight below 10 kg.</p><p><em><u>Elderly</u></em></p><p>Results of a population pharmacokinetic analysis including both young and elderly patients with epilepsy, enrolled in the same trials, indicated that the clearance of lamotrigine did not change to a clinically relevant extent. After single doses apparent clearance decreased by 12% from 35 mL/min at age 20 to 31 mL/min at 70 years. The decrease after 48 weeks of treatment was 10% from 41 to 37 mL/min between the young and elderly groups. In addition, pharmacokinetics of lamotrigine was studied in 12 healthy elderly subjects following a 150 mg single dose. The mean clearance in the elderly (0.39 mL/min/kg) lies within the range of the mean clearance values (0.31 to 0.65 mL/min/kg) obtained in nine studies with non-elderly adults after single doses of 30 to 450 mg.</p><p><u><em>Renal impairment</em></u></p><p>Twelve volunteers with chronic renal failure, and another six individuals undergoing hemodialysis were each given a single 100 mg dose of lamotrigine. Mean clearances were 0.42 mL/min/kg (chronic renal failure), 0.33 mL/min/kg (between hemodialysis) and 1.57 mL/min/kg (during hemodialysis), compared with 0.58 mL/min/kg in healthy volunteers. Mean plasma half-lives were 42.9 hours (chronic renal failure), 57.4 hours (between hemodialysis) and 13.0 hours (during hemodialysis), compared with 26.2 hours in healthy volunteers. On average, approximately 20% (range = 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated during a 4-hour hemodialysis session. For this patient population, initial doses of lamotrigine should be based on the patient&#39;s concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment (see sections 4.2 and 4.4).</p><p><u><em>Hepatic impairment</em></u></p><p>A single dose pharmacokinetic study was performed in 24 subjects with various degrees of hepatic impairment and 12 healthy subjects as controls. The median apparent clearance of lamotrigine was 0.31, 0.24 or 0.10 mL/min/kg in patients with Grade A, B, or C (Child-Pugh Classification) hepatic impairment, respectively, compared with 0.34 mL/min/kg in the healthy controls. Initial, escalation and maintenance doses should generally be reduced in patients with moderate or severe hepatic impairment (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.</p><p>In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but reduced foetal weight and retarded skeletal ossification were observed, at exposure levels below or similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to the severity of maternal toxicity, the teratogenic potential of lamotrigine has not been characterised above clinical exposure.</p><p>In rats, enhanced foetal as well as post-natal mortality was observed when lamotrigine was administered during late gestation and through the early post-natal period. These effects were observed at the expected clinical exposure.</p><p>In juvenile rats, an effect on learning in the Biel maze test, a slight delay in balanopreputial separation and vaginal patency and a decreased postnatal body weight gain in F1 animals were observed at exposures approximately two-times higher than the therapeutic exposures in human adults. Animal experiments did not reveal impairment of fertility by lamotrigine. Lamotrigine reduced foetal folic acid levels in rats. Folic acid deficiency is assumed to be associated with an enhanced risk of congenital malformations in animals as well as in humans. Lamotrigine caused a dose-related inhibition of the hERG channel tail current in human embryonic kidney cells. The IC50 was approximately nine-times above the maximum therapeutic free concentration. Lamotrigine did not cause QT prolongation in animals at exposures up to approximately two-times the maximum therapeutic free concentration. In a clinical study, there was no clinically significant effect of lamotrigine on QT interval in healthy adult volunteers (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>25, 50, and 100 mg tablets:</p><p>Lactose BP 200</p><p>Avicel PH 101</p><p>Sodium starch glycolate</p><p>Iron oxide yellow</p><p>Povidone30</p><p>Purified water</p><p>Avicel PH 102</p><p>Colloidal silicon dioxide</p><p>Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:730px"><tbody><tr><td style="vertical-align:top"><p>Not applicable.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25, 50, and 100 mg tablets:
24 months/ 2 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>25, 50, and 100 mg tablets:</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lamira 25 mg tablets: Transparent thermoformed PVC/PE/PVDC blister and hard aluminum foil. Each unit carton contains 30 tablets.</p><p>Lamira 50 mg tablets: Transparent thermoformed PVC/PE/PVDC blister and hard aluminum foil. Each unit carton contains 30 tablets.</p><p>Lamira 100 mg tablets: Transparent thermoformed PVC/PE/PVDC blister and hard aluminum foil. Each unit carton contains 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Spimaco
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>